# GLP-1 Drugs Causing Unexpected Heart Rate Changes in Athletic Users
Athletes taking GLP-1 weight-loss medications like semaglutide and tirzepatide are reporting unusual changes in heart rate, heart rate variability (HRV), and aerobic capacity that have experts scrambling for answers.
The phenomenon emerged when fit individuals noticed their wearable fitness trackers showed sudden drops in VO2 max and elevated resting heart rates despite maintaining their usual training regimens. Many initially assumed their devices were malfunctioning. The pattern repeated across multiple athletes, suggesting something real was happening at the physiological level.
Cardiologists and sports medicine specialists are still investigating the mechanism. The drugs work by slowing gastric emptying and reducing appetite through GLP-1 receptor agonism, but the cardiovascular effects remain unclear. Some researchers hypothesize the medications alter cardiovascular efficiency during exercise or change how the heart distributes blood flow. Others suggest metabolic shifts from rapid weight loss might temporarily stress cardiac adaptation.
The changes appear most pronounced in athletes already tracking performance metrics obsessively through devices like Oura rings and Whoop bands, making the effects highly visible. Not all users report these shifts, and the degree of change varies considerably between individuals.
Sports cardiologists caution that the long-term implications remain unknown. While GLP-1 drugs show cardiovascular benefits for people with diabetes and heart disease, athletic populations represent a different physiological context. The medications weren't developed or tested extensively in high-performing athletes.
Current guidance remains limited. Some practitioners recommend athletes consult cardiologists before starting GLP-1 therapy. Others suggest waiting to see if cardiovascular metrics stabilize as bodies adapt to the drugs over weeks or months.
The racing community is watching closely. Professional athletes already push cardiovascular limits, and introducing a variable with unknown effects